mitomycin has been researched along with Experimental Mammary Neoplasms in 50 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| " MMC microspheres, alone or combined with Dox microspheres, were injected i." | 1.33 | In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations. ( Cheung, RY; Rauth, AM; Yu Wu, X, 2005) |
| "Mitomycin C (MMC) is an anticancer, antibiotic that is currently used clinically against a wide variety of tumors." | 1.30 | A new cellular target for mitomycin C: a case for mitochondrial DNA. ( Briggs, LA; Gustafson, DL; Pritsos, CA, 1997) |
| "Mitomycin C (MMC) is a bioreductive antitumor agent that is activated by NADPH:cytochrome P450 reductase (EC 1." | 1.29 | Induction of DT-diaphorase by doxorubicin and combination therapy with mitomycin C in vitro. ( Begleiter, A; Leith, MK, 1995) |
| " In the present study we have evaluated the therapeutic efficacy of pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid) combined with mitomycin C (MMC) on bone metastasis of breast cancer using an animal model." | 1.29 | Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model. ( Enomoto, K; Ikeda, T; Ishii, S; Kitajima, M; Tamura, H; Wada, N, 1996) |
| "Mitomycin C is an antineoplastic antibiotic requiring bioactivation to an alkylating species or to an intermediate capable of generating oxygen radicals for its toxic effect." | 1.28 | Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. ( Gustafson, DL; Pritsos, CA, 1992) |
| " We now demonstrate that DIC sensitizes EMT6 cells to two MC analogues, porfiromycin (POR) and the 7-N-dimethylaminomethylene analogue of mitomycin C (BMY-25282), in hypoxia and protects cells from these agents in air, despite the fact that POR is preferentially toxic to hypoxic cells and BMY-25282 is preferentially toxic to aerobic cells." | 1.28 | Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells. ( Keyes, SR; Rockwell, S; Sartorelli, AC, 1989) |
| "Mitomycin C (MC) and its structural analogs porfiromycin (PM), BMY-25282 and BL-6783 are toxic to EMT6 cells under aerobic and hypoxic conditions." | 1.28 | Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics. ( Keyes, SR; Pritsos, CA; Sartorelli, AC, 1989) |
| "The effects of mitomycin C alone and in combination with radiation on the cells of EMT6 mouse mammary tumors in BALB/cKaRw mice were examined." | 1.27 | Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo. ( Rockwell, S, 1983) |
| " Hypoxic fractions (HF) were calculated by an indirect technique using the horizontal displacement of the TCD50 value from the dose-response curves of tumors irradiated under normal or clamped conditions." | 1.27 | Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. ( Grau, C; Overgaard, J, 1988) |
| " These findings suggested that dicoumarol might enhance the toxicity of MC to the hypoxic cells of solid tumors, without increasing the toxic side effects of the antibiotic to the host." | 1.27 | Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. ( Keyes, SR; Rockwell, S; Sartorelli, AC, 1985) |
| "Mitomycin C (MC) was more toxic to EMT6 mouse mammary tumor cells in vitro under hypoxia than under aerobic conditions." | 1.27 | Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. ( Rockwell, S, 1986) |
| " Agents which are preferentially toxic to cells with low oxygen contents could therefore be useful as adjuncts to the regimens now used to treat these cancers." | 1.27 | Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. ( Keyes, SR; Rockwell, S; Sartorelli, AC, 1985) |
| " The cytotoxicities of the two agents were found to be additive as judged by comparing dose-response curves for each agent alone with survival curves after combination therapy and by isobologram analysis." | 1.26 | Cytotoxicities of mitomycin C and x rays to aerobic and hypoxic cells in vitro. ( Rockwell, S, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (52.00) | 18.7374 |
| 1990's | 18 (36.00) | 18.2507 |
| 2000's | 4 (8.00) | 29.6817 |
| 2010's | 2 (4.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shuhendler, AJ | 1 |
| Prasad, P | 1 |
| Zhang, RX | 1 |
| Amini, MA | 1 |
| Sun, M | 1 |
| Liu, PP | 1 |
| Bristow, RG | 1 |
| Rauth, AM | 3 |
| Wu, XY | 2 |
| Zhou, QM | 2 |
| Zhang, H | 2 |
| Lu, YY | 2 |
| Wang, XF | 2 |
| Su, SB | 2 |
| Liu, XJ | 1 |
| Huang, S | 1 |
| Cowen, RL | 1 |
| Patterson, AV | 1 |
| Telfer, BA | 1 |
| Airley, RE | 1 |
| Hobbs, S | 1 |
| Phillips, RM | 1 |
| Jaffar, M | 1 |
| Stratford, IJ | 1 |
| Williams, KJ | 1 |
| Cheung, RY | 2 |
| Yu Wu, X | 1 |
| Ronaldson, PT | 1 |
| Bendayan, R | 1 |
| Mitani, M | 1 |
| Iwano, K | 1 |
| Arika, T | 1 |
| Kikuchi, M | 1 |
| Imanaka, K | 2 |
| Gose, K | 2 |
| Ichiyanagi, A | 1 |
| Ashida, C | 1 |
| Hamada, F | 1 |
| Hashimura, T | 1 |
| Takimoto, S | 1 |
| Murakami, M | 1 |
| Imajo, Y | 2 |
| Kimura, S | 3 |
| Ogawa, Y | 2 |
| Maeda, T | 1 |
| Yoshida, S | 1 |
| Yamamoto, Y | 1 |
| Morita, M | 1 |
| Rockwell, S | 16 |
| Hyodo, M | 2 |
| Ito, N | 1 |
| Suzuki, K | 2 |
| Keyes, SR | 8 |
| Fracasso, PM | 2 |
| Heimbrook, DC | 2 |
| Sligar, SG | 2 |
| Sartorelli, AC | 11 |
| Koh, J | 1 |
| Asanuma, F | 1 |
| Kurihara, H | 1 |
| Konno, H | 1 |
| Kubouchi, K | 1 |
| Ikeda, T | 2 |
| Enomoto, K | 2 |
| Ishibiki, K | 1 |
| Abe, O | 1 |
| Kubota, T | 1 |
| Begleiter, A | 1 |
| Leith, MK | 1 |
| Belcourt, MF | 1 |
| Hodnick, WF | 2 |
| Pritsos, CA | 4 |
| Bizanek, R | 1 |
| Chowdary, D | 1 |
| Arai, H | 1 |
| Kasai, M | 1 |
| Hughes, CS | 3 |
| Tomasz, M | 1 |
| Chirrey, L | 2 |
| Cummings, J | 2 |
| Halbert, GW | 2 |
| Smyth, JF | 2 |
| Ohasi, K | 1 |
| Satonaka, K | 1 |
| Yamamoto, T | 1 |
| Yamazaki, M | 1 |
| Abe, S | 1 |
| Yamaguchi, H | 1 |
| Willmott, N | 1 |
| Shao, Y | 1 |
| Pardini, L | 2 |
| Pardini, RS | 2 |
| Kelley, M | 1 |
| Tamura, H | 1 |
| Ishii, S | 1 |
| Wada, N | 1 |
| Kitajima, M | 1 |
| Briggs, LA | 1 |
| Gustafson, DL | 2 |
| Rossi, I | 1 |
| Nicoletti, G | 1 |
| Landuzzi, L | 1 |
| Frabetti, F | 1 |
| De Giovanni, C | 1 |
| Nanni, P | 1 |
| Musiani, P | 1 |
| Ferrantini, M | 1 |
| Belardelli, F | 1 |
| Lollini, PL | 1 |
| Wan, ZG | 1 |
| Kobayashi, H | 1 |
| Hayakawa, A | 1 |
| Ishigaki, T | 1 |
| Kennedy, KA | 3 |
| Grau, C | 2 |
| Overgaard, J | 2 |
| Mimnaugh, EG | 1 |
| Trush, MA | 1 |
| Sinha, BK | 1 |
| von der Maase, H | 1 |
| Borgeson, CE | 1 |
| Reitz, RC | 1 |
| Monge, OR | 1 |
| Rofstad, EK | 1 |
| Kaalhus, O | 1 |
| Kreider, JW | 1 |
| Howell, LE | 1 |
| Bartlett, GL | 1 |
| Kanno, S | 1 |
| Ohkido, M | 1 |
| McGurl, JD | 1 |
| Leondaridis, L | 1 |
| Alabaster, O | 1 |
| Teicher, BA | 1 |
| Gunner, LJ | 1 |
| Roach, JA | 1 |
50 other studies available for mitomycin and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cell Line, Tumor; Doxorubic | 2014 |
Curcumin reduced the side effects of mitomycin C by inhibiting GRP58-mediated DNA cross-linking in MCF-7 breast cancer xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cross-Linking Reagents; Curcumin; DNA; DNA D | 2009 |
Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tum | 2011 |
Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
Topics: Adenoviridae; Animals; Antibiotics, Antineoplastic; DNA, Neoplasm; Drug Delivery Systems; Drug Resis | 2003 |
In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Delayed-Action Preparations; D | 2005 |
In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blott | 2006 |
[Experimental study on immunochemotherapy using schizophyllan].
Topics: Adjuvants, Immunologic; Animals; Glycosaminoglycans; Macrophage Activation; Male; Mammary Neoplasms, | 1982 |
[Experimental study on active specific immunotherapy utilizing the immune reaction of low-dose irradiated tumor tissue. 8. Effect of mitomycin C-treated active specific immunotherapy].
Topics: Animals; Cell Survival; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mitomycin; | 1983 |
[Experimental study on active specific immunotherapy utilizing the immune reaction of low-dose irradiated tumor tissue. 9. Effect of the mitomycin C-treated, cryopreserved immune reaction combined with biological response modifier, OK-432].
Topics: Animals; Biological Products; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mitom | 1983 |
Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
Topics: Animals; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Mammary Neoplas | 1983 |
Deoxynucleoside triphosphate pool of mouse FM3A cell lines unaffected by mutagen treatment.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Deoxyribonucleotides; Female; Mammary Neoplasms, Ex | 1984 |
Combination therapy with misonidazole and mitomycin C: lack of chemosensitization of EMT6 tumor cells in vivo or in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 1984 |
Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
Topics: Animals; Antibiotics, Antineoplastic; Biotransformation; Cell Line; Cricetinae; Cricetulus; Cytochro | 1984 |
[Experimental chemotherapy of human breast carcinomas transplanted into nude mice].
Topics: Aclarubicin; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 1984 |
Cytotoxicities of mitomycin C and x rays to aerobic and hypoxic cells in vitro.
Topics: Aerobiosis; Anaerobiosis; Animals; Antineoplastic Agents; Cell Line; Cell Survival; Dose-Response Re | 1982 |
Induction of DT-diaphorase by doxorubicin and combination therapy with mitomycin C in vitro.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Survival; Cells, Cultured; Doxorubicin; Drug Syner | 1995 |
Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin.
Topics: Animals; Antibiotics, Antineoplastic; Cell Hypoxia; Cell Survival; Free Radicals; Hydroxyl Radical; | 1995 |
Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.
Topics: Aerobiosis; Animals; Cell Hypoxia; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; D | 1993 |
Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo.
Topics: Animals; Biotransformation; Chromatography, High Pressure Liquid; Half-Life; Mammary Neoplasms, Expe | 1995 |
Combination therapy with radiation, mitomycin C, and 5-fluorouracil in EMT6 tumors.
Topics: Animals; Cell Survival; Combined Modality Therapy; Fluorouracil; In Vitro Techniques; Mammary Neopla | 1994 |
[Antitumor activity of Enterococcus faecalis FK-23 preparation against murine syngeneic tumors].
Topics: Animals; Biological Products; Combined Modality Therapy; Cyclophosphamide; Enterococcus faecalis; Ma | 1993 |
Reductive activation of mitomycin C by NADH:cytochrome b5 reductase.
Topics: Aerobiosis; Alkylation; Animals; Biotransformation; Cell Hypoxia; Cell Line; Cytochrome Reductases; | 1993 |
Determination of mitomycin C, 2,7-diaminomitosene, 1,2-cis- and 1,2-trans-1-hydroxy-2,7-diaminomitosene in tumour tissue by high-performance liquid chromatography.
Topics: Animals; Chromatography, High Pressure Liquid; Female; Hydrogen-Ion Concentration; Mammary Neoplasms | 1993 |
Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1.
Topics: Animals; Catalase; Dietary Fats, Unsaturated; Female; Fish Oils; Glutathione; Glutathione Peroxidase | 1995 |
Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.
Topics: Aerobiosis; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Cell Hypoxia; C | 1996 |
Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Neoplasms; Diphosphonates; | 1996 |
A new cellular target for mitomycin C: a case for mitochondrial DNA.
Topics: Adenosine Triphosphate; Animals; Antibiotics, Antineoplastic; DNA, Mitochondrial; Dose-Response Rela | 1997 |
Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells.
Topics: Adenocarcinoma; Animals; Cancer Vaccines; Female; Injections, Intraperitoneal; Injections, Intraveno | 1998 |
A diffusible resistance factor(s) in spontaneous mitomycin resistant mammalian cancer cells.
Topics: Animals; Antibiotics, Antineoplastic; Cell Cycle; Cell Division; Cell Survival; Culture Media, Condi | 1998 |
Effects of mitomycin C and porfiromycin on exponentially growing and plateau phase cultures.
Topics: Aerobiosis; Anaerobiosis; Animals; Antibiotics, Antineoplastic; Cell Division; Female; Mammary Neopl | 1994 |
Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors.
Topics: Animals; Biotransformation; Female; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Mic | 1992 |
Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors.
Topics: Acid-Base Equilibrium; Aging; Animals; Antineoplastic Agents; Combined Modality Therapy; Female; Lis | 1991 |
Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Re | 1991 |
Effects of glutathione and ethylxanthate on mitomycin C activation by isolated rat hepatic or EMT6 mouse mammary tumor nuclei.
Topics: Animals; Biotransformation; Cell Nucleus; Dicumarol; Edetic Acid; Glutathione; Hot Temperature; In V | 1985 |
The role of mitomycin antibiotics in the chemotherapy of solid tumors.
Topics: Anaerobiosis; Animals; Biotransformation; Cytochromes; Dicumarol; Drug Synergism; Female; Mammary Ne | 1986 |
Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumour.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclopho | 1986 |
Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro.
Topics: Animals; Cell Line; Cell Survival; Dicumarol; Drug Synergism; Hypoxia; Mammary Neoplasms, Experiment | 1988 |
Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; D | 1988 |
Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
Topics: Aerobiosis; Alkylating Agents; Anaerobiosis; Animals; Biological Transport; Cell Line; Cell Survival | 1989 |
Effects of dietary fish oil on human mammary carcinoma and on lipid-metabolizing enzymes.
Topics: Acyltransferases; Animals; Body Weight; Carnitine Acyltransferases; Dietary Fats, Unsaturated; Doxor | 1989 |
Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
Topics: Aerobiosis; Animals; Cell Hypoxia; Cell Survival; Ditiocarb; DNA Damage; Free Radicals; Mammary Neop | 1989 |
Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
Topics: Anaerobiosis; Animals; Antibiotics, Antineoplastic; Cell Line; Cell Survival; Combined Modality Ther | 1985 |
Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro.
Topics: Animals; Cell Division; Cell Survival; Cells, Cultured; Culture Media; Hydrogen-Ion Concentration; I | 1986 |
Thermochemotherapy in vivo of a C3H mouse mammary carcinoma: single fraction heat and drug treatment.
Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Hype | 1988 |
Characteristics of T cells involved in the expression of delayed hypersensitivity and tumor rejection immunity to 13762A rat mammary adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antigens, Surface; Cyclophosphamide; Female; Hydroxyure | 1985 |
Effect of DNA-damaging agents on DNA replication and cell-cycle progression of cultured mouse mammary carcinoma cells.
Topics: Animals; Cell Cycle; Cells, Cultured; Cisplatin; Cross-Linking Reagents; DNA Replication; DNA, Neopl | 1985 |
pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells.
Topics: Animals; Aziridines; Benzoquinones; Biotransformation; Buffers; Cell Line; Cross-Linking Reagents; D | 1985 |
Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
Topics: Alkylating Agents; Animals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Female | 1985 |
Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Cell Survival; Cricetinae; Female; Mammary Neoplasm | 1985 |
Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Cell Survival; Cisplatin; Dose-Response Relationshi | 1985 |